The new funding allows the company to begin producing vaccine patches for clinical studies. In addition, it permits MyLife to invest with partners in demonstration projects targeting COVID-19, human papilloma virus, and a variety of cancers.

MyLife said it foresees a series A investment round of an estimated $17.5 million in early 2023 for the construction of a pilot plant and expansion of activities to the U.S. and Asia.

MyLife Ceramic Skin Patch allows for the simple, efficient, and painless administration of vaccines through the skin. Image courtesy of MyLife Technologies.